Evidence map›Paper›PMID 19406319›Full record

ReviewThe Urologic clinics of North America2009

Nanotechnology in urology.

Shihua Jin, Vinod Labhasetwar

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Urologic clinics of North America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Urological technology: where will we be in 20 years' time?Therapeutic advances in urology · 2018
    Review
  2. Urovision 2020: The future of urology.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Shihua JinDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Vinod Labhasetwar
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · US

Funding

Nuclear-targeted nanoparticles for gene deliveryR01EB003975 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LABHASETWAR, VINOD D · 2005 to 2008
$1.1M
Drug Resistance in Cancer TherapyR21CA121751 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LABHASETWAR, VINOD D · 2006 to 2007
$282k
NCI NIH HHS R21 CA121751NIBIB NIH HHS R01 EB003975
6 · The paper itself

Abstract

Nanomedicine is a new distinct scientific discipline that explores applications of nanoscale materials for various biomedical applications. Translational nanomedicine is undergoing rapid transition from development and evaluation in laboratory animals to clinical practices. In the future, it is anticipated that nanotechnology can provide urologists a new point of view to understand the mechanism of disease, tools for early diagnosis of the disease, and effective modality for treatment. This article summarizes some of the emerging applications of nanomedicine in urology.

Indexed as

NanomedicineDiagnostic ImagingDrug CarriersHumansNanostructuresPolymorphism, Single NucleotideUrologic DiseasesDrug Carriers

Identifiers

PMID19406319
PMCPMC2676239
OpenAlexW1981486896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.